Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Oct;119(3):564–568. doi: 10.1111/j.1476-5381.1996.tb15709.x

Characteristics of cyanopindolol analogues active at the beta 3-adrenoceptor in rat ileum.

A J Hoey 1, C M Jackson 1, G G Pegg 1, M N Sillence 1
PMCID: PMC1915720  PMID: 8894179

Abstract

1. Cyanopindolol (CYP) is a potent antagonist at the beta 3-adrenoceptor in rat ileum. Several analogues of CYP and pindolol were synthesized that also produced antagonist effects at the beta 3-adrenoceptor. However, at high concentrations, these compounds appear to act as "partial agonists'. This study was conducted to determine the structural requirements of CYP analogues necessary for antagonist activity and to examine the possibility that the agonist effects of CYP and its analogues may occur through a mechanism independent of beta-adrenoceptor activation. 2. Analogues of CYP and pindolol were tested for antagonist activity in rat ileum in which the beta 1- and beta 2-adrenoceptors were blocked. Fourteen compounds were tested against (-)-isoprenaline, and four of the more potent analogues were then tested against BRL 37344. The two most potent antagonists were CYP and iodocyanopindolol. The pKb values (negative log of equilibrium dissociation constant) obtained against (-)-isoprenaline were significantly higher than those obtained against BRL 37344, but the cause of this difference is not known. 3. Several structural requirements were determined for antagonist activity. Modification at the carbon atom alpha to the secondary amine caused the antagonist potency to fall as the level of saturation was reduced. Thus, a quaternary carbon group, such as t-butyl, produced the most potent antagonist. Substitution with a large moiety such as a cyclohexyl or benzyl group reduced antagonist activity, probably due to steric hindrance. Inclusion of an electron-withdrawing group, such as a cyano or ethylester moiety, alpha to the indole nitrogen, also increased the potency. Iodination of CYP and ethylesterpindolol at the 3-position of the indole ring did not increase antagonist potency. In contrast, iodination of the almost inactive analogues produced a significant increase in potency, suggesting that a beneficial electronic effect on the indole ring imparted by the iodo moiety may be able to offset partially the negative effects caused by either the steric hindrance, of lack of a quaternary carbon alpha to the secondary amine. 4. Values for pseudo-pD2 were also determined by conducting cumulative concentration-response studies up to the limit of drug solubility. For nine of the compounds tested, the pKb was significantly higher than the pseudo-pD2 value. 5. The discrepancy between the pKb and pseudo-pD2 values was examined further. The agonist effects of iodocyanopindolol, the agonist with the highest potency, were not antagonized by CYP which was the most potent antagonist of (-)-isoprenaline and BRL 37344 at the beta 3-adrenoceptor. This suggests that the agonist effects of iodoCYP were produced through a different mechanism: either via another receptor, another isoform of the rat beta 3-adrenoceptor, or through a non-receptor-mediated effect. Pseudo-pD2 values did not correlate with log P values for these compounds, indicating that their relaxant effects were not simply a function of their lipid solubility. 6. This study has highlighted several structural requirements for antagonist binding potency at the rat ileum beta 3-adrenoceptor and should assist in the development of potent selective antagonists for this receptor.

Full text

PDF
564

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arch J. R., Ainsworth A. T., Cawthorne M. A., Piercy V., Sennitt M. V., Thody V. E., Wilson C., Wilson S. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature. 1984 May 10;309(5964):163–165. doi: 10.1038/309163a0. [DOI] [PubMed] [Google Scholar]
  2. Blin N., Camoin L., Maigret B., Strosberg A. D. Structural and conformational features determining selective signal transduction in the beta 3-adrenergic receptor. Mol Pharmacol. 1993 Dec;44(6):1094–1104. [PubMed] [Google Scholar]
  3. Granneman J. G., Lahners K. N., Chaudhry A. Molecular cloning and expression of the rat beta 3-adrenergic receptor. Mol Pharmacol. 1991 Dec;40(6):895–899. [PubMed] [Google Scholar]
  4. Granneman J. G., Whitty C. J. CGP 12177A modulates brown fat adenylate cyclase activity by interacting with two distinct receptor sites. J Pharmacol Exp Ther. 1991 Feb;256(2):421–425. [PubMed] [Google Scholar]
  5. Growcott J. W., Wilson C., Holloway B., Mainwaring S. Evaluation of ICI D7114, a putative stimulant of brown adipocytes, on histamine-contracted guinea-pig ileum. Br J Pharmacol. 1993 Aug;109(4):1212–1218. doi: 10.1111/j.1476-5381.1993.tb13751.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hoey A., Jackson C., Pegg G., Sillence M. Atypical responses of rat ileum to pindolol, cyanopindolol and iodocyanopindolol. Br J Pharmacol. 1996 Feb;117(4):712–716. doi: 10.1111/j.1476-5381.1996.tb15248.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Johnson J. A. Racial differences in lymphocyte beta-receptor sensitivity to propranolol. Life Sci. 1993;53(4):297–304. doi: 10.1016/0024-3205(93)90748-r. [DOI] [PubMed] [Google Scholar]
  8. Kaumann A. J. Is there a third heart beta-adrenoceptor? Trends Pharmacol Sci. 1989 Aug;10(8):316–320. doi: 10.1016/0165-6147(89)90065-5. [DOI] [PubMed] [Google Scholar]
  9. MacDonald A., Forbes I. J., Gallacher D., Heeps G., McLaughlin D. P. Adrenoceptors mediating relaxation to catecholamines in rat isolated jejunum. Br J Pharmacol. 1994 Jun;112(2):576–578. doi: 10.1111/j.1476-5381.1994.tb13113.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. MacKay D. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? J Pharm Pharmacol. 1978 May;30(5):312–313. doi: 10.1111/j.2042-7158.1978.tb13237.x. [DOI] [PubMed] [Google Scholar]
  11. McLaughlin D. P., MacDonald A. Characterization of catecholamine-mediated relaxations in rat isolated gastric fundus: evidence for an atypical beta-adrenoceptor. Br J Pharmacol. 1991 Jun;103(2):1351–1356. doi: 10.1111/j.1476-5381.1991.tb09792.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. McLaughlin D. P., MacDonald A. Evidence for the existence of 'atypical' beta-adrenoceptors (beta 3-adrenoceptors) mediating relaxation in the rat distal colon in vitro. Br J Pharmacol. 1990 Nov;101(3):569–574. doi: 10.1111/j.1476-5381.1990.tb14122.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Moretti-Rojas I., Ezrailson E. G., Birnbaumer L., Entman M. L., Garber A. J. Serotonergic and adrenergic regulation of skeletal muscle metabolism in the rat. II. The use of [125I]iodolysergic acid diethylamide and [125I]iodopindolol as probes of sarcolemmal receptor function and specificity. J Biol Chem. 1983 Oct 25;258(20):12499–12508. [PubMed] [Google Scholar]
  14. Muzzin P., Revelli J. P., Kuhne F., Gocayne J. D., McCombie W. R., Venter J. C., Giacobino J. P., Fraser C. M. An adipose tissue-specific beta-adrenergic receptor. Molecular cloning and down-regulation in obesity. J Biol Chem. 1991 Dec 15;266(35):24053–24058. [PubMed] [Google Scholar]
  15. Roberts S. J., Molenaar P., Summers R. J. Characterization of propranolol-resistant (-)-[125I]-cyanopindolol binding sites in rat soleus muscle. Br J Pharmacol. 1993 Jun;109(2):344–352. doi: 10.1111/j.1476-5381.1993.tb13576.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Roffel A. F., Meurs H., Elzinga C. R., Zaagsma J. No evidence for a role of muscarinic M2 receptors in functional antagonism in bovine trachea. Br J Pharmacol. 1995 Jun;115(4):665–671. doi: 10.1111/j.1476-5381.1995.tb14984.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sugasawa T., Matsuzaki M., Morooka S., Foignant N., Blin N., Strosberg A. D. In vitro study of a novel atypical beta-adrenoceptor agonist, SM-11044. Eur J Pharmacol. 1992 Jun 5;216(2):207–215. doi: 10.1016/0014-2999(92)90362-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES